Prognostic impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study
- PMID: 35580601
- DOI: 10.1093/eurjpc/zwac093
Prognostic impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study
Abstract
Aims: To compare prognosis between individuals without diabetes, type 1 and type 2 diabetes in a nationwide atrial fibrillation cohort in Sweden and study the significance of severe hypoglycaemia.
Methods: Using data from all-inclusive national registers, 309,611 patients with non-valvular atrial fibrillation were enrolled during 2013-2014. Of these, 2,221 had type 1 and 58,073 had type 2 diabetes. Patients were followed for all-cause mortality until 27 March 2017, and for myocardial infarction, ischaemic stroke and first-ever diagnosis of heart failure or dementia until 31 December 2015. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox and competing risk regression.
Results: Using individuals without diabetes as reference (HR = 1), the adjusted HRs in type 1 vs. type 2 diabetes were for mortality 1.87 (CI 1.73-2.02) vs. 1.51 (CI 1.47-1.55), heart failure 1.59 (CI 1.42-1.78) vs. 1.41 (CI 1.34-1.48), myocardial infarction 2.49 (CI 2.17-2.85) vs. 1.70 (CI 1.59-1.81), ischaemic stroke 1.59 (CI 1.35-1.87) vs. 1.31 (CI 1.22-1.40), and dementia 1.46 (CI 1.15-1.85) vs. 1.28 (CI 1.18-1.40). Among individuals with type 2 diabetes, those with previous severe hypoglycaemia had increased risk of mortality (HR 1.26; CI 1.17-1.36) and dementia (HR 1.37; CI 1.08-1.73) compared with those without previous severe hypoglycaemia.
Conclusion: Presence of diabetes-regardless of type- in atrial fibrillation is associated with an increased risk of premature death, cardiovascular events and dementia. This increase is more pronounced in type 1 than in type 2 diabetes. A history of severe hypoglycaemia is associated with a worsened prognosis in type 2 diabetes.
Keywords: Atrial fibrillation; Dementia; Heart failure; Hypoglycaemia; Mortality; Myocardial infarction; Prognosis; Stroke; Type 1 diabetes; Type 2 diabetes.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Conflict of interest: The authors declare that they have no conflicts of interest concerning this study. S.K. reports personal fees from Astra Zeneca, Boehringer Ingelheim, and Novo Nordisk. A.N. reports personal fees from Astra Zeneca, MSD, Boehringer Ingelheim, Lilly, and Novo Nordisk. L.L.-H. reports personal fees from Novo-Nordisk. L.F. reports personal fees from Bayer, Boehringer Ingelheim, BMS, Pfizer, and Sanofi. P.L. reports personal fees from Boehringer Ingelheim, Sanofi, and Novo Nordisk.
Comment in
-
Diabetes and atrial fibrillation: does the type of diabetes matter?Eur J Prev Cardiol. 2022 Oct 18;29(13):1756-1758. doi: 10.1093/eurjpc/zwac131. Eur J Prev Cardiol. 2022. PMID: 35776833 No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
